The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without Co-morbidities

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 6, 2011, Pages 414-420

  Minas, Markos ^a   Kostikas, Konstantinos ^a   Papaioannou, Andriana I ^a   Mystridou, Parthena ^a   Karetsi, Eleni ^a   Georgoulias, Panagiotis ^a   Liakos, Nikolaos ^a   Pournaras, Spyros ^a   Gourgoulianis, Konstantinos I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Adiponectin; COPD; FFMI; HOMA index; Leptin; Metabolic Syndrome

Indexed keywords

ADIPONECTIN; CARBON MONOXIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AGED; AIRWAY OBSTRUCTION; ARTERIAL GAS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; FUNCTIONAL RESIDUAL CAPACITY; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HORMONE BLOOD LEVEL; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; INSULIN RESISTANCE; LUNG FUNCTION TEST; MALE; METABOLIC STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; TOTAL LUNG CAPACITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; AGE FACTORS; AGED; BODY MASS INDEX; HUMANS; INSULIN RESISTANCE; LEPTIN; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 83155167553     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.619600     Document Type: Article

References (43)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176(6):532-555. (Pubitemid 47403272)
2. SinDD,Man SF. Skeletalmuscleweakness, reduced exercise tolerance, andCOPD: is systemic inflammation themissing link?Thorax 2006 Jan; 61(1):1-3. (Pubitemid 43106967)
3. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Dec; 160(6):1856-1861. (Pubitemid 30004687)
4. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sorensen TI, Lange P. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a randompopulation sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006 Jan 1; 173(1):79-83. (Pubitemid 43069791)
5. Slinde F, Gronberg A, Engstrom CP, Rossander-Hulthen L, Larsson S. Body composition by bioelectrical impedance predictsmortality in chronic obstructive pulmonary disease patients. Respir Med 2005 Aug; 99(8):1004-1009. (Pubitemid 40796543)
6. Kao TW, Lu IS, Liao KC, Lai HY, Loh CH, Kuo HK. Associations between body mass index and serum levels of C-reactive protein. S Afr Med J 2009 May; 99(5):326-330.
7. Breyer MK, SpruitMA, Celis AP, Rutten EP, Janssen PP,Wouters EF. Highly elevated C-reactive protein levels in obese patients with COPD: a fat chance? Clin Nutr 2009 Dec; 28(6):642-647.
8. Steuten LM, Creutzberg EC, Vrijhoef HJ, Wouters EF. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006 Apr; 15(2):84-91.
9. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008 Dec; 29(24):2959-2971.
10. Bruno A, Chanez P, Chiappara G, Siena L, Giammanco S, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM. Does leptin play a cytokine-like role within the airways of COPD patients? Eur Respir J 2005 Sep; 26(3):398-405. (Pubitemid 41264200)
11. Krommidas G, Kostikas K, Papatheodorou G, Koutsokera A, Gourgoulianis KI, Roussos C, Koulouris NG, Loukides S. Plasma leptin and adiponectin in COPD exacerbations: Associations with inflammatory biomarkers. Respir Med 2010 Jan; 104(1):40-46.
12. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3):356-359. (Pubitemid 34251969)
13. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004 Jan 27; 109(3):433-438. (Pubitemid 38133916)
14. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009 Oct; 136(4):1039-1046.
15. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascularmorbidity. Int J Chron Obstruct Pulmon Dis 2009; 4(3):337-349.
16. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major co-morbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010 Nov; 65(11):956-962.
17. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988 Mar; 93(3):580-586.
18. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995 Sep; 152(3):1107-1136.
19. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002 Jul 1; 166(1):111-117.
20. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. Georges Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145(6):1321-1327.
21. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C. Bioelectrical impedance analysis-part I: reviewof principles and methods. ClinNutr 2004 Oct; 23(5):1226-1243. (Pubitemid 39243041)
22. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, ManuelGomez J, Lilienthal Heitmann B, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, MWJ Schols A, Pichard C. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr 2004 Dec; 23(6):1430-1453. (Pubitemid 39517638)
23. VanItallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalized indices of the bodys fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr 1990 Dec; 52(6):953-959. (Pubitemid 120008197)
24. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar 4; 350(10):1005-1012. (Pubitemid 38269277)
25. Ip MS, LamB,NgMM,LamWK, TsangKW, LamKS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002 Mar 1; 165(5):670-676. (Pubitemid 34194755)
26. Watz H, Waschki B, Boehme C, ClaussenM,Meyer T,Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008 Apr 1; 177(7):743-751. (Pubitemid 351490561)
27. Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, Poirier P. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005 Jul-Aug; 25(4):226-232; discussion 33-34. (Pubitemid 41153761)
28. Poulain M, Doucet M, Drapeau V, Fournier G, Tremblay A, Poirier P, Maltais F. Metabolic and inflammatory profile in obese patientswith chronic obstructive pulmonary disease. Chron Respir Dis 2008; 5(1):35-41. (Pubitemid 351903614)
29. Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, Lam TH, Cheng KK, Adab P. Airflow obstruction and the metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010 Feb; 35(2):317-323.
30. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010 Apr; 25(4):253-260.
31. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006 Jan; 100(1):115-122. (Pubitemid 43039873)
32. Sidney S, SorelM,Quesenberry CP, Jr.,DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005 Oct; 128(4):2068-2075. (Pubitemid 41507542)
33. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, Tanou K, Nikoulis DJ, Georgoulias P, Zakynthinos E, Gourgoulianis KI, Kostikas K. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 2010 Feb; 104(2):275-282.
34. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, De Rosa E, Fabbri LM, Mapp CE. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006 Dec; 61(12):1037-1042. (Pubitemid 44852020)
35. Gnacinska M, Malgorzewicz S, Stojek M, Lysiak-Szydlowska W, Sworczak K. Role of adipokines in complications related to obesity. A review. Adv Med Sci 2009 Oct; 29:1-8.
36. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007 Jul; 132(1):164-169. (Pubitemid 47068217)
37. Stenholm S, Koster A, Alley DE, Visser M, Maggio M, Harris TB, Egan JM, Bandinelli S, Guralnik JM, Ferrucci L. Adipocytokines and the metabolic syndrome among older persons with and without obesity - the InCHIANTI Study. Clin Endocrinol (Oxf) 2010 Jul; 73(1):55-65.
38. Bolton CE, Evans M, Ionescu AA, Edwards SM,Morris RH, DunseathG, Luzio SD, OwensDR, ShaleDJ. Insulin resistance and inflammation- A further systemic complication of COPD. COPD 2007 Jun; 4(2):121-126. (Pubitemid 47164861)
39. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of co-morbidities. Eur Respir J 2006 Dec; 28(6):1245-1257.
40. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, Pare C, Freixa X, Ferrer J, Ferrer A, Roca J, Galdiz JB, Sauleda J,MonsoE,Gea J, Barbera JA, Agusti A, Anto JM. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011May; 66(5):430-437.
41. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008 Jan; 31(1):204-212.
42. Ku IA, Farzaneh-Far R, Vittinghoff E, ZhangMH, Na B, Whooley MA. Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 2011 Aug; 217(2):503-508.
43. Pilz S, Maerz W, Weihrauch G, Sargsyan K, Almer G, Nauck M, Boehm BO, Winkelmann BR, Mangge H. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2006 Feb; 364(1-2):251-255. (Pubitemid 43120651)